Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

INTRODUCTION: Insulin-like growth factor signaling has been implicated in acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. This phase 1 trial (NCT02191891) investigated the combination of xentuzumab (an insulin-like growth factor-ligand neutralizing monoclonal antibody) and af...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Keunchil, Tan, Daniel Shao Weng, Su, Wu-Chou, Cho, Byoung Chul, Kim, Sang-We, Lee, Ki Hyeong, Wang, Chin-Chou, Seto, Takashi, Huang, Dennis Chin-Lun, Jung, Helen Hayoun, Hsu, Ming-Chi, Bogenrieder, Thomas, Lin, Chia-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474216/
https://www.ncbi.nlm.nih.gov/pubmed/34590052
http://dx.doi.org/10.1016/j.jtocrr.2021.100206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474216/
https://www.ncbi.nlm.nih.gov/pubmed/34590052
http://dx.doi.org/10.1016/j.jtocrr.2021.100206

Ejemplares similares